Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Says No To Australian Approval Process For Personalized Devices

Executive Summary

Respondents to a consultation by the Therapeutic Goods Administration on how to adequately regulate personalized medical devices are against the proposed introduction of an application and approval process. But they do favor other proposals that would bolster the rules, particularly for 3D-printed products.

You may also be interested in...



Australia Tries Again At Tightening Personalized And 3D-Printed Device Rules

The Therapeutics Goods Administration has begun a second public consultation on how it intends to improve its rules for 3D-printed and other personalized medical devices after stakeholders called for more clarification to proposals made in 2017.

International Regulators Seek To Improve Oversight Of Personalized Devices

Regulations that govern custom-made medical devices in some regions might no longer be appropriate, according to the International Medical Device Regulators Forum, which is seeking feedback on a new set of definitions for personalized products.

EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions

After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT122722

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel